These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 33837821)

  • 1. Inflammatory markers in autoimmunity induced by checkpoint inhibitors.
    Husain B; Kirchberger MC; Erdmann M; Schüpferling S; Abolhassani AR; Fröhlich W; Berking C; Heinzerling L
    J Cancer Res Clin Oncol; 2021 Jun; 147(6):1623-1630. PubMed ID: 33837821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy - A multicentre study of 90 patients from the German Dermatooncology Group.
    Grimmelmann I; Momma M; Zimmer L; Hassel JC; Heinzerling L; Pföhler C; Loquai C; Ruini C; Utikal J; Thoms KM; Kähler KC; Eigentler T; Herbst RA; Meier F; Debus D; Berking C; Kochanek C; Ugurel S; Gutzmer R;
    Eur J Cancer; 2021 May; 149():1-10. PubMed ID: 33812141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C-reactive protein as a biomarker for immune-related adverse events in melanoma patients treated with immune checkpoint inhibitors in the adjuvant setting.
    Lauwyck J; Beckwée A; Santens A; Schwarze JK; Awada G; Vandersleyen V; Aspeslagh S; Neyns B
    Melanoma Res; 2021 Aug; 31(4):371-377. PubMed ID: 34054056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Checkpoint-blocker-induced autoimmunity is associated with favourable outcome in metastatic melanoma and distinct T-cell expression profiles.
    Ye W; Olsson-Brown A; Watson RA; Cheung VTF; Morgan RD; Nassiri I; Cooper R; Taylor CA; Akbani U; Brain O; Matin RN; Coupe N; Middleton MR; Coles M; Sacco JJ; Payne MJ; Fairfax BP
    Br J Cancer; 2021 May; 124(10):1661-1669. PubMed ID: 33723392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report.
    Hultin S; Nahar K; Menzies AM; Long GV; Fernando SL; Atkinson V; Cebon J; Wong MG
    BMC Nephrol; 2020 Sep; 21(1):391. PubMed ID: 32894101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition.
    Laino AS; Woods D; Vassallo M; Qian X; Tang H; Wind-Rotolo M; Weber J
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing immune checkpoint blockade in metastatic uveal melanoma: exploring the association of overall survival and the occurrence of adverse events.
    Koch EAT; Petzold A; Dippel E; Erdmann M; Gesierich A; Gutzmer R; Hassel JC; Haferkamp S; Kähler KC; Kreuzberg N; Leiter U; Loquai C; Meier F; Meissner M; Mohr P; Pföhler C; Rahimi F; Schell B; Terheyden P; Thoms KM; Ugurel S; Ulrich J; Utikal J; Weichenthal M; Ziller F; Berking C; Heppt MV
    Front Immunol; 2024; 15():1395225. PubMed ID: 38915414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autoantibody profiles in patients with immune checkpoint inhibitor-induced neurological immune related adverse events.
    Müller-Jensen L; Knauss S; Ginesta Roque L; Schinke C; Maierhof SK; Bartels F; Finke C; Rentzsch K; Ulrich C; Mohr R; Stenzel W; Endres M; Boehmerle W; Huehnchen P
    Front Immunol; 2023; 14():1108116. PubMed ID: 36845122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of S100 protein and MIA protein as serum marker for malignant melanoma.
    Djukanovic D; Hofmann U; Sucker A; Rittgen W; Schadendorf D
    Anticancer Res; 2000; 20(3B):2203-7. PubMed ID: 10928178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endocrine immune-related adverse events by immune checkpoint inhibitors and potential predictive markers: a prospective study from a single tertiary center.
    Barlas T; Sutcuoglu O; Akdogan O; Balos Toruner F; Akturk M; Ozdemir N; Yazici O; Eroglu Altinova A
    Endocr Relat Cancer; 2024 Nov; 31(11):. PubMed ID: 39194584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy.
    Dimitriou F; Hogan S; Menzies AM; Dummer R; Long GV
    Eur J Cancer; 2021 Nov; 157():214-224. PubMed ID: 34536945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tyrosine Protein Kinase SYK-Related Gene Signature in Baseline Immune Cells Associated with Adjuvant Immunotherapy-Induced Immune-Related Adverse Events in Melanoma.
    Monson KR; Ferguson R; Handzlik JE; Xiong J; Dagayev S; Morales L; Chat V; Bunis A; Sreenivasaiah C; Dolfi S; Tenney DJ; Shao Y; Osman I; Weber JS; Kirchhoff T
    Clin Cancer Res; 2024 Oct; 30(19):4412-4423. PubMed ID: 39115425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lower baseline autoantibody levels are associated with immune-related adverse events from immune checkpoint inhibition.
    Ghosh N; Postow M; Zhu C; Jannat-Khah D; Li QZ; Vitone G; Chan KK; Bass AR
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35091456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity.
    Gutzmer R; Koop A; Meier F; Hassel JC; Terheyden P; Zimmer L; Heinzerling L; Ugurel S; Pföhler C; Gesierich A; Livingstone E; Satzger I; Kähler KC;
    Eur J Cancer; 2017 Apr; 75():24-32. PubMed ID: 28214654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative imaging biomarkers of immune-related adverse events in immune-checkpoint blockade-treated metastatic melanoma patients: a pilot study.
    Hribernik N; Huff DT; Studen A; Zevnik K; Klaneček Ž; Emamekhoo H; Škalic K; Jeraj R; Reberšek M
    Eur J Nucl Med Mol Imaging; 2022 May; 49(6):1857-1869. PubMed ID: 34958422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Endocrine side effects of cancer immunotherapy].
    Kroiß M; Schilling B; Deutschbein T
    Dtsch Med Wochenschr; 2020 Dec; 145(24):1736-1741. PubMed ID: 33254246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events.
    Shahabi V; Berman D; Chasalow SD; Wang L; Tsuchihashi Z; Hu B; Panting L; Jure-Kunkel M; Ji RR
    J Transl Med; 2013 Mar; 11():75. PubMed ID: 23521917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlative Monitoring of Immune Activation and Tissue Damage in Malignant Melanoma-An Algorithm for Identification of Tolerance Breakage During Immune Checkpoint Inhibitor Therapy of Cancer.
    Wahl RU; Leijs M; Araujo A; Rübben A
    Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32188047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hematological immune related adverse events after treatment with immune checkpoint inhibitors.
    Kramer R; Zaremba A; Moreira A; Ugurel S; Johnson DB; Hassel JC; Salzmann M; Gesierich A; Weppler A; Spain L; Loquai C; Dudda M; Pföhler C; Hepner A; Long GV; Menzies AM; Carlino MS; Sachse MM; Lebbé C; Baroudjian B; Enokida T; Tahara M; Schlaak M; Hayani K; Bröckelmann PJ; Meier F; Reinhardt L; Friedlander P; Eigentler T; Kähler KC; Berking C; Zimmer L; Heinzerling L
    Eur J Cancer; 2021 Apr; 147():170-181. PubMed ID: 33706206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. S-100B protein and melanoma inhibitory activity protein in uveal melanoma screening. A comparison with liver function tests.
    Missotten GS; Korse CM; van Dehn C; Linders TC; Keunen JE; Jager MJ; Bonfrer JM
    Tumour Biol; 2007; 28(2):63-9. PubMed ID: 17264538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.